<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783587</url>
  </required_header>
  <id_info>
    <org_study_id>12-267</org_study_id>
    <nct_id>NCT01783587</nct_id>
  </id_info>
  <brief_title>Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer</brief_title>
  <official_title>Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is a Phase I clinical trial. Phase I clinical trials test the safety of&#xD;
      an investigational drug. Phase I studies also try to define the appropriate dose of the&#xD;
      investigational drug to use for further studies. &quot;Investigational&quot; means that the drug is&#xD;
      still being studied and that research doctors are trying to find out more about it-such as&#xD;
      the safest dose to use and the side effects it may cause.&#xD;
&#xD;
      Afatinib has been studied in other clinical trials of participants with head and neck cancer,&#xD;
      lung cancer, and breast cancer. This dose of Afatinib has also been studied in other research&#xD;
      studies. This is the first clinical trial to study Afatinib in combination with Radiation&#xD;
      Therapy.&#xD;
&#xD;
      The purpose of this study is to determine the safest dose of Afatinib when given in&#xD;
      combination with Radiation Therapy or in combination with Radiation Therapy and chemotherapy&#xD;
      for head and neck cancer.&#xD;
&#xD;
      Afatinib is a drug that may stop cancer cells from growing abnormally. This drug works by&#xD;
      blocking multiple proteins known to play a role in the growth of cancer cells. Information&#xD;
      from laboratory research studies suggests that this drug may help to make head and neck&#xD;
      cancer cells more sensitive to Radiation Therapy.&#xD;
&#xD;
      The other therapy in this research study is Radiation Therapy or Radiation Therapy plus a&#xD;
      chemotherapy drug called Docetaxel. After surgery, Radiation Therapy and chemotherapy is the&#xD;
      standard treatment if you have high risk disease. &quot;High risk disease&quot; means that without&#xD;
      additional therapy, there is a high risk that the disease may return. In this study,&#xD;
      participants with high-risk disease will receive Radiation Therapy and Docetaxel and&#xD;
      Afatinib. &quot;Intermediate risk&quot; means that there is an intermediate risk that the disease may&#xD;
      return. Radiation Therapy alone is the standard treatment approach for intermediate risk&#xD;
      cancer. In this study, participants with intermediate risk disease will receive Radiation&#xD;
      Therapy and Afatinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If you are willing to take part in this study you will be asked to undergo some screening&#xD;
      tests and procedures to confirm your eligibility. Many of these tests and procedures are&#xD;
      likely to be part of regular cancer care and may be done even if you do not take part in the&#xD;
      research study. If you already had some of these tests and procedures recently, they may or&#xD;
      may not have to be repeated. The tests and procedures include: a review of your medical&#xD;
      history, physical exam, blood samples, urine sample, serum pregnancy test, electrocardiogram,&#xD;
      echocardiogram and an assessment of your disease to find out the extent of your cancer. If&#xD;
      these tests show that you are eligible to participate in the research study, you may begin&#xD;
      the study treatment. If you do not meet the eligibility criteria, you will not be able to&#xD;
      participate in this research study.&#xD;
&#xD;
      We will collect an archive tumor specimen (leftover tissue from your prior surgery or&#xD;
      biopsies) to confirm your cancer diagnosis. Additional tests on the tumor specimen may be&#xD;
      performed as a part of future studies to gain new knowledge about head and neck cancer.&#xD;
&#xD;
      You will receive Afatinib as a pill that you take by mouth for 7 weeks. During the first&#xD;
      week, you will receive Afatinib alone. During the second through seventh weeks, you will&#xD;
      receive Afatinib together with Radiation Therapy OR with Docetaxel and Radiation Therapy.&#xD;
      Docetaxel is given intravenously, once a week during Week 2 through Week 7. Not everyone who&#xD;
      participates in this research study will receive the same dose of the study drug. The dose&#xD;
      you get will depend on the number of participants who have been enrolled in the study before&#xD;
      you and how well they tolerated their doses.&#xD;
&#xD;
      Afatinib needs to be taken on an empty stomach. Specific instructions about this will be&#xD;
      included in the drug diary you will need to complete.&#xD;
&#xD;
      If you take part in this research study, you will receive the same radiation that you would&#xD;
      receive if you were not on the study. The radiation is typically done daily Monday through&#xD;
      Friday for about 6-7 weeks. You will sign a separate consent form with your radiation&#xD;
      oncologist that will outline what to expect with this treatment.&#xD;
&#xD;
      You will be given a physical exam every week during your treatment. You will have a physical&#xD;
      exam and be asked questions about your general health and specific questions about any&#xD;
      problems that you might be having and any medications you may be taking.&#xD;
&#xD;
      You will have blood tests every week during your treatment including chemistry and hematology&#xD;
      tests and a pregnancy test if you are a woman capable of becoming pregnant before you receive&#xD;
      your first infusion of docetaxel.&#xD;
&#xD;
      You will also be asked to return to the clinic one week, four weeks and eight weeks after&#xD;
      finishing your treatment. Most of these visits are part of routine visits after finishing&#xD;
      treatment. If you stop the study early for any reason, you will also have a clinic visit. In&#xD;
      either instance, the following exams and procedures will be performed: physical exam, blood&#xD;
      tests, other tests including an electrocardiogram, MUGA scan or echocardiogram, CT scan and a&#xD;
      PET/CT scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 20, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The presence or absence of a dose-limiting toxicity at a given dose-level of afatinib.</measure>
    <time_frame>7 weeks</time_frame>
    <description>All participants who receive any amount of study drug will be evaluable for toxicity. The primary outcome measure is the incidence of a physician-assessed dose-limiting toxicity (DLT) at a given dose-level of afatinib. Participants will be assessed for a DLT at least once per week during the course of therapy, including the one-week afatinib lead-in period and the 6-7 weeks of radiation therapy. DLT's are defined as the incidence of a severe or life-threatening toxicity (grade 3-4) as defined by the Common Terminology Criteria for Adverse Events Versions 4 (CTCAEv.4) or any afatinib-related toxicity requiring a dose reduction occurring during treatment with afatinib and radiation therapy +/- docetaxel. Participants will continue to be assessed for adverse events for 12 weeks after the completion of therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>High Risk Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of afatinib + docetaxel + radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate Risk Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of afatinib + radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Taken orally once per day</description>
    <arm_group_label>High Risk Group</arm_group_label>
    <arm_group_label>Intermediate Risk Group</arm_group_label>
    <other_name>Gilotrif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>15 mg/m2, given intravenously once per week</description>
    <arm_group_label>High Risk Group</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Daily, Monday-Friday, for six to seven weeks</description>
    <arm_group_label>High Risk Group</arm_group_label>
    <arm_group_label>Intermediate Risk Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven diagnosis of squamous cell carcinoma of the head and neck&#xD;
&#xD;
          -  Pathology from the primary surgery must be reviewed and finalized at either the&#xD;
             Dana-Farber Cancer Institute/Brigham &amp; Women's Hospital or the pathology department at&#xD;
             any participating institution&#xD;
&#xD;
          -  Status post gross total resection with curative intent&#xD;
&#xD;
          -  Primary tumor site: oral cavity, oropharynx, larynx, hypopharynx&#xD;
&#xD;
          -  Disease must be defined as either high-risk or intermediate risk&#xD;
&#xD;
          -  Definition of high-risk: Any of the following high-risk features: positive margins&#xD;
             (defined as tumor at ink), extracapsular extension of lymph node, gross T4a or T4b&#xD;
             primary tumor, any lymph node â‰¥ 6cm (N3)&#xD;
&#xD;
          -  Definition of intermediate-risk: Absence of any high-risk features AND any one of the&#xD;
             following intermediate risk features: Two or more positive lymph nodes involved with&#xD;
             squamous cell carcinoma, single lymph node &gt;3cm and &lt;6cm, perineural invasion,&#xD;
             lymphovascular invasion, Level IV or level V involvement of oral cavity or&#xD;
             oropharyngeal tumors, or T2 oral cavity tumor with &gt;5mm depth of invasion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior anti-epidermal growth factor (EGF) or anti-Human Epidermal Growth Factor&#xD;
             Receptor-2 (HER2) therapy&#xD;
&#xD;
          -  Prior radiation therapy to the head and neck&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Receiving other study agents&#xD;
&#xD;
          -  History of interstitial lung disease&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy&#xD;
&#xD;
          -  Active or prior malignancy except non-melanoma skin cancer&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to afatinib or docetaxel&#xD;
&#xD;
          -  Cardiac left ventricular dysfunction&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  HIV positive on combination antiretroviral therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle Margalit, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 30, 2013</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Danielle Margalit, MD, MPH</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

